UNSPSC 51291507: Ebalzotan

This classification denotes a serotonin agonist and antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WV4B56N49H. European Medicines Agency schedules Ebalzotan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06434MIG. Ebalzotan generally arises in the molecular formula C19H30N2O2. The term EBALZOTAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, no. 3, 1995, list 35.) Most nations schedule ebalzotan under HS 29329985 and SITC 51569.

As of Q4 2014, EBALZOTAN remains the US FDA Preferred Term for this commodity. Ebalzotan bears US NLM identifiers UMLS ID C2348371 and NCI Concept Code C72746. SMILES: O1CC(N(C(C)C)CCC)Cc2c1cccc2C(=O)NC(C)C.

UNSPSC 51291507 Ebalzotan, a Commodity code, does not align with the state and local procurement activity recently tagged under it. The three most recent opportunities—Seminole County's naloxone and drug deactivation systems procurement, the Texas HHS Commission's therapeutic pharmacy initiative RFI, and the Minnesota MMCAP generic pharmaceutical and OTC products RFP—involve pharmaceutical products, pharmacy benefit management, and drug distribution systems, none of which relate to Ebalzotan, a pharmaceutical compound with a narrowly defined therapeutic scope. State and local procurement records show minimal or no recent activity in the actual commodity this code nominates, suggesting either sparse demand, misclassification in the source data, or a mismatch between the code's intended scope and current government purchasing practice.

The issuing bodies across these opportunities span state health and human services departments (Texas HHS Commission, Minnesota Department of Administration) and county public health procurement (Seminole County, Florida), indicating that pharmaceutical and drug-related procurement flows through diverse state, county, and cooperative purchasing channels. Geographic activity centers on Texas, Minnesota, and Florida, with Minnesota's MMCAP structure serving multiple states including Oregon. Representative recent solicitations include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response date of July 26, 2023; the Texas HHS Commission's RFI on direct-to-manufacturer prescription programs posted April 3, 2026; and the Minnesota MMCAP RFP for generic multi-source pharmaceuticals and OTC products with a proposal deadline of March 26, 2026. None of these opportunities are actually purchasing Ebalzotan; the code assignment in the source appears to be an error or misapplication.